Episodes
Friday Oct 16, 2020
Extracting Data on CBD: Effects on Opioid Use and Quality of Life
Friday Oct 16, 2020
Friday Oct 16, 2020
Sales of cannabinoid-containing products continue to rise. In 2020 it became a billion-dollar industry. With the increased use and popularity of CBD products, every clinician needs to critically appraise the evidence to determine if CBD should play a role in pain management and help educate patients about the potential risks.
Guest Author: Alex R. Mills, PharmD, BCACP, AAHIVP
Music by Good Talk
Friday Oct 02, 2020
I Screen, You Screen, We Should All Screen for Unhealthy Drug Use
Friday Oct 02, 2020
Friday Oct 02, 2020
Nearly 1 in 8 Americans older than 12 used illicit substances in 2018, including misuse of prescription medications. In addition, more than 80% of those who would benefit from substance use treatment in the past year did not receive it. Thus, the importance of identifying and offering treatment should be a priority — particularly in primary care settings. However, there are many barriers to implementing unhealthy substance use screening including pervasive stigma, lack of clinician comfort, logistics, and limited knowledge of or avenues for treatment when unhealthy drug use is uncovered. The US Preventative Services Task Force (USPSTF) recently published updated recommendations on drug use screening.
Guest Authors: Melissa C. Palmer, PharmD, BCPS, BCPP; Jordan Cooler, PharmD, BCPP; and Amanda Stahnke, PharmD, BCACP
Music by Good Talk
Friday Aug 02, 2019
Improving Access to Naloxone - Yes, Pharmacists (Nar)CAN!
Friday Aug 02, 2019
Friday Aug 02, 2019
The opioid overdose epidemic, primarily driven by potent synthetic opioids, has rapidly intensified in recent years. Overdose education and naloxone distribution (OEND) efforts appear to have a positive impact on opioid-overdose mortality. As many states continue to expand naloxone access through various legislation efforts, it’s important to identify which laws have the greatest impact on reducing fatal opioid overdoses.
Guest Authors: Scott Coon, PharmD, BCPS, BCACP and Matthew Thomas, PharmD
Music by Good Talk
Friday Mar 30, 2018
Treating Opioid Use Disorder - X:BOT Offers a Pragmatic Approach
Friday Mar 30, 2018
Friday Mar 30, 2018
Opioid-use disorder (OUD), a risk factor and major contributor to opioid-related deaths, is often underdiagnosed and undertreated. Currently there are three FDA-approved pharmacologic treatments for OUD maintenance therapy: methadone, buprenorphine (with or without naloxone), and naltrexone. Despite definitive evidence that methadone and buprenorphine products are effective in the treatment of OUD, there are still considerable accessibility and availability barriers that patients face when seeking Medication Assisted Treatment (MAT). The EXtended-release naltrexone vs Buprenorphine/naloxone for Opioid Treatment (X:BOT) trial compared the efficacy and safety of XR-NTX and BUP-NX to induce and maintain a patient with OUD on MAT as well as reducing opioid overdoses, relapses, and cravings.
Guest Author: Jordan L. Wulz, PharmD, MPH, BC-ADM, CHC
Music by Good Talk
Friday Nov 10, 2017
Painstaking Efforts to Improve Opioid Stewardship
Friday Nov 10, 2017
Friday Nov 10, 2017
Drug overdose is now the leading cause of death among Americans under the age of 50. In 2016, the United States (U.S.) Centers for Disease Control and Prevention (CDC) released a seminal guideline for primary care clinicians regarding opioid prescribing. These guidelines are now being implemented by clinicians, insurers, and healthcare institutions. The Transforming Opioid Prescribing in Primary Care (TOPCARE) study sought to assess the impact of a multicomponent care management intervention on opioid stewardship in four primary care centers.
Guest Authors: Lucas Hill and Jennifer Shin
Music by Good Talk
Friday Oct 21, 2016
Opioid Safety and Overdose Prevention
Friday Oct 21, 2016
Friday Oct 21, 2016
While narcotic analgesics remain a mainstay for the treatment of acute and chronic pain, urgent care visits and deaths from opioid overdoses have skyrocketed. Our panelists are Dr. Lucas Hill from the University of Texas at Austin and Jeffrey Bratberg from the University of Rhode Island. Dr. Hill practices in a primary care setting and maintains the iForumRx Opioid Safety and Overdose Prevention Resource Page. Dr. Bratberg helped develop, implement, and expand the Collaborative Pharmacy Practice for Naloxone Partnership in Rhode Island. Drs. Hill and Bratberg describe how healthprofessionals - particularly ambulatory care pharmacists - can take action to improve the safe use of opioids and prevent overdoses.